| Epithelial Neoplasm altered in cohorts of …ALTERED_INderived200 of 941show all (up to 200) |
|---|
| ← altered in cohorts of | HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf158 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMK2N1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMTA1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAPZB 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCN6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDOST 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | E2F2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM43B 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO42 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMGCL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPR 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HP1BP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPG2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR1D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IFFO2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF21 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KDM1A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LACTBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LDLRAD2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC38 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LUZP1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFAP2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10-NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MST1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPHP4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OTUD3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAX7 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDIK1L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDPN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PINK1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PITHD1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2C 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2E 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2F 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHG5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF12 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF14 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF18 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF20 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF25 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF26 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF27 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF33 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF9 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAP1GAP 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCC2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF186 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC66A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPEN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TEX46 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP48 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS13D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF436 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYC 138 / 185 cases (75 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POU5F1B 138 / 185 cases (75 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 276 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNQ3 135 / 185 cases (73 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7B 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LENEP 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GSDMC 134 / 185 cases (72 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRATD2 134 / 185 cases (72 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CKS1B 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PYGO2 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXFP4 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHC1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNA 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3A 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMVK 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RYR2 413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 23 cohorts | — | — | Lung Adenocarcinoma | 23 | Observed | gdc | graph → |
| ← altered in cohorts of | CDKN2B 133 / 185 cases (72 %) · ssm · TCGA-ESCA · largest of 2 cohorts | — | — | Esophageal Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFR3A 133 / 185 cases (72 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCT3 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3L 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ISG20L2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC71 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MNDA 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTRK1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMF1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB25 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA4A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D2A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SSR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM79 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HDGF 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NIT1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR6Y1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP1 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCN4 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HHLA1 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDRBS3 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC6 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDRG1 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OC90 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLA 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIB1 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZFAT 132 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG 406 / 573 cases (71 %) · ssm · TCGA-LUAD · largest of 17 cohorts | — | — | Lung Adenocarcinoma | 17 | Observed | gdc | graph → |
| ← altered in cohorts of | CYRIB 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHF20L1 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ST3GAL1 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM71 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WASHC5 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF572 131 / 185 cases (71 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTRT3 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCHE 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC31 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRIQ4 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCEH1 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NSMCE2 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDCD10 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SAMD7 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SQLE 130 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USH2A 402 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 22 cohorts | — | — | Lung Adenocarcinoma | 22 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPTA1 400 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 18 cohorts | — | — | Lung Adenocarcinoma | 18 | Observed | gdc | graph → |
| ← altered in cohorts of | ATAD2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF5A2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3B 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC34 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPL13 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTBP 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYNN 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHC3 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF139 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22L1 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC62 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC14A1 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC14A2 129 / 185 cases (70 %) · ssm · TCGA-ESCA · largest of 2 cohorts | — | — | Esophageal Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC2A2 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC7A14 129 / 185 cases (70 %) · ssm · TCGA-ESCA | — | — | Esophageal Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLITRK3 129 / 185 cases (70 %) · ssm · TCGA-ESCA · largest of 2 cohorts | — | — | Esophageal Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ST8SIA5 129 / 185 cases (70 %) · ssm · TCGA-ESCA · largest of 2 cohorts | — | — | Esophageal Carcinoma | 2 | Observed | gdc | graph → |